A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Clinical trial NCT06246916 · RECRUITING
Trial details
- NCT number
- NCT06246916
- Sponsor
- Regeneron Pharmaceuticals
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-09-09
- Primary completion
- 2027-03-22
- Enrollment
- 560
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.